International review of 94 probiotic supplements containing Lactobacillus acidophilus DDS-1 found only 2 products passed all relevant criteria for IBS symptom management.

Last updated 4 October 2024 | Results reviewed by Daniel Keats RDN

1.1 Passed key criteria

This research project contains no affiliate links, sponsored products or ads.
Products are graded using transparent criteria and methodology.
Any commercially available product can be submitted for grading.
Results are published publicly without alteration.

 

View Methodology | Submit a Product

1.2 Table of results

Order of Results: Product names are listed alphabetically within each category.

Explanation of criteria

  1. Transparent Formula: The supplement’s ingredients and their amounts are openly labeled, not hidden behind proprietary blends. This transparency is essential for us to verify that it meets the studied dose requirements.
  2. Studied Dose: For DDS-1 in IBS populations, the effective dose is 10 billion CFUs per day. Any product that delivers this specific dose in one or more servings meets this criterion.
  3. IBS RCT Probiotics Only: The product contains only probiotic strains that have been studied in IBS populations through randomized, placebo-controlled clinical trials. No other active ingredients are included, as unstudied additives may alter efficacy.
  4. Third-Party Tested CFUs: The manufacturer has submitted the product for third-party testing to verify both the CFU count (amount of probiotics in finished product) and has published the results on their website.
  5. Availability: Indicates where the product can be purchased. Please note that consumers worldwide can often access USA and UK products using a forwarding service.

1.3 Summary

  • We searched the entire web to find and evaluate products containing DDS-1.
  • 94 products were found containing DDS-1.
  • 58 products were excluded due to a lack of transparency; they do not disclose their formula or the amounts of each ingredient, making it impossible to confirm if they provide the clinically studied dose.
  • 27 products failed as they could not be served at the studied dose – i.e. could not be expanded or divided to deliver the 10 billion CFU dose that has been studied for DDS-1.
    • This includes 14 products that were served in “incompatible” doses. i.e. they contained DDS-1 along with other probiotic strain(s) that have been studied in IBS populations, but failed to deliver all of the strains at their respective studied dose amounts.
  • 5 products failed because they contained additional active ingredients that are not probiotics studied in randomized controlled trials for IBS populations.
  • 1 product was excluded because it has been discontinued.
  • This means that only 3 products met all our key criteria. Of these, no products published third-party testing results on their website.

Is a product missing?
Submit a product suggestion here.

Products are free to submit. We do not accept payment. Products are strictly graded using transparent and verifiable information.